Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec to commence phase IIIb Tysabri study

Biogen Idec to commence phase IIIb Tysabri study

27th January 2012

Biogen Idec is set to begin a phase IIIb clinical trial of Tysabri as a treatment for secondary-progressive multiple sclerosis (SPMS).

The double-blind placebo-controlled Ascend trial will involve 850 patients across 15 countries and will assess the benefits of the drug among SPMS patients over 96 weeks.

SPMS is a severely debilitating form of MS that leads to a steady progression of nerve damage, symptoms and disability, which can severely impact a patient's mobility, independence and quality of life.

Moreover, National Multiple Sclerosis Society figures from the US show that around half of all people initially diagnosed with relapsing-remitting MS – the most common form of the disease – transition to SPMS within 19 years.

Professor Richard Reynolds, professor of cellular neuroscience at Imperial College London, said: "Preliminary data suggests that Tysabri may hinder inflammation in the brain and reduce SPMS-related disease progression; therefore, further investigation of this hypothesis is warranted."

Tysabri is approved in more than 65 countries, showing benefits such as the ability to reduce annualised relapse rates while providing incontinence-related quality of life benefits.ADNFCR-8000103-ID-801276555-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.